Core Insights - The company anticipates a 2025 earnings shortfall due to significant challenges in three specific surgical hospital markets, rather than broader systemic issues [1] Performance Analysis - Performance was negatively impacted by an unexpected shift in payer mix, with newly recruited physicians treating more Medicare patients and ramping up slower than historical cohorts [1] - A transition occurred where retiring high-volume commercial surgeons were replaced by physicians with a lower commercial mix, adversely affecting top-line margins [1] - Operational deleverage was noted as labor and anesthesia coverage costs did not adjust quickly enough to the changing volume and payer mix in the latter half of the year [1] Growth Opportunities - High-acuity procedure growth was a positive aspect, with total joint replacements increasing by 19% year-to-date, supported by the deployment of 74 surgical robots [1] Strategic Direction - The company is moving towards a 'short-stay' surgical strategy, which involves divesting or partnering with larger surgical hospitals that no longer align with the core model [1] - Management has recognized execution gaps and has appointed new leadership, including a new COO, to stabilize underperforming hospital markets [1]